{"id":"shr6390-tablets","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4802161","moleculeType":"Small molecule","molecularWeight":"446.56"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting Nav1.5, SHR6390 is expected to reduce the risk of atrial fibrillation and its associated complications. This is achieved by modulating the electrical activity in the heart, thereby preventing the irregular heart rhythms associated with atrial fibrillation.","oneSentence":"SHR6390 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:32.384Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT05328440","phase":"PHASE2","title":"Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2022-05-20","conditions":"Breast Neoplasms","enrollment":120},{"nctId":"NCT04989829","phase":"PHASE1","title":"Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-12-27","conditions":"Advanced Solid Tumor","enrollment":20},{"nctId":"NCT04293276","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2020-04-01","conditions":"Metastatic Breast Cancer","enrollment":41},{"nctId":"NCT05515289","phase":"PHASE1","title":"Study of SHR6390 in Renal Insufficiency and Healthy Subjects","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-12-18","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT04301804","phase":"PHASE1","title":"A Trial of SHR6390 in Healthy Caucasian Volunteers","status":"COMPLETED","sponsor":"Atridia Pty Ltd.","startDate":"2020-03-12","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT05189717","phase":"PHASE1","title":"A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults","status":"UNKNOWN","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2022-02-17","conditions":"Metastatic or Local Advanced Breast Cancer of Patients","enrollment":156},{"nctId":"NCT04973020","phase":"PHASE1","title":"A Drug-drug Interaction Study of SHR6390 on Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-09-01","conditions":"Advanced Solid Tumor","enrollment":20},{"nctId":"NCT04423601","phase":"PHASE1","title":"Effect of Itraconazole on the Pharmacokinetics of SHR6390 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-06-10","conditions":"Healthy Subjects","enrollment":18},{"nctId":"NCT04439578","phase":"PHASE1","title":"Effect of Rifampicin on the Pharmacokinetics of SHR6390 in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-06-23","conditions":"Healthy Subjects","enrollment":18},{"nctId":"NCT03966898","phase":"PHASE3","title":"A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-07-19","conditions":"Advanced Breast Cancer","enrollment":426},{"nctId":"NCT04479891","phase":"PHASE1","title":"Effect of Itraconazole on the Pharmacokinetics of Pyrotinib in Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-09-18","conditions":"Healthy Subjects","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR6390 Tablets","genericName":"SHR6390 Tablets","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR6390 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5. Used for Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}